Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/HIF1A_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/HIF1A_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/HIF1A_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/HIF1A_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/HIF1A_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/HIF1A_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/HIF1A_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/HIF1A_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/HIF1A_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/HIF1A_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/HIF1A_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00017821 | Colorectum | MSS | B cell homeostasis | 12/3467 | 31/18723 | 6.80e-03 | 4.39e-02 | 12 |
GO:20003772 | Colorectum | MSS | regulation of reactive oxygen species metabolic process | 42/3467 | 157/18723 | 6.83e-03 | 4.40e-02 | 42 |
GO:0031929 | Colorectum | MSS | TOR signaling | 35/3467 | 126/18723 | 6.91e-03 | 4.44e-02 | 35 |
GO:0050678 | Colorectum | MSS | regulation of epithelial cell proliferation | 90/3467 | 381/18723 | 6.92e-03 | 4.45e-02 | 90 |
GO:19012152 | Colorectum | MSS | negative regulation of neuron death | 53/3467 | 208/18723 | 7.60e-03 | 4.77e-02 | 53 |
GO:0048762 | Colorectum | MSS | mesenchymal cell differentiation | 59/3467 | 236/18723 | 7.79e-03 | 4.84e-02 | 59 |
GO:00716041 | Colorectum | MSS | transforming growth factor beta production | 15/3467 | 43/18723 | 8.06e-03 | 4.91e-02 | 15 |
GO:00513532 | Colorectum | MSS | positive regulation of oxidoreductase activity | 19/3467 | 59/18723 | 8.19e-03 | 4.97e-02 | 19 |
GO:1900542 | Colorectum | MSS | regulation of purine nucleotide metabolic process | 25/3467 | 84/18723 | 8.27e-03 | 4.99e-02 | 25 |
GO:00460344 | Colorectum | FAP | ATP metabolic process | 87/2622 | 277/18723 | 6.50e-14 | 6.63e-11 | 87 |
GO:00060914 | Colorectum | FAP | generation of precursor metabolites and energy | 128/2622 | 490/18723 | 5.58e-13 | 4.28e-10 | 128 |
GO:00098964 | Colorectum | FAP | positive regulation of catabolic process | 126/2622 | 492/18723 | 3.76e-12 | 2.56e-09 | 126 |
GO:00313314 | Colorectum | FAP | positive regulation of cellular catabolic process | 110/2622 | 427/18723 | 6.09e-11 | 2.19e-08 | 110 |
GO:00091504 | Colorectum | FAP | purine ribonucleotide metabolic process | 96/2622 | 368/18723 | 4.91e-10 | 1.20e-07 | 96 |
GO:00159804 | Colorectum | FAP | energy derivation by oxidation of organic compounds | 85/2622 | 318/18723 | 1.36e-09 | 2.77e-07 | 85 |
GO:00061634 | Colorectum | FAP | purine nucleotide metabolic process | 100/2622 | 396/18723 | 1.45e-09 | 2.77e-07 | 100 |
GO:00092593 | Colorectum | FAP | ribonucleotide metabolic process | 97/2622 | 385/18723 | 2.90e-09 | 5.07e-07 | 97 |
GO:00516563 | Colorectum | FAP | establishment of organelle localization | 97/2622 | 390/18723 | 5.91e-09 | 9.48e-07 | 97 |
GO:00090604 | Colorectum | FAP | aerobic respiration | 57/2622 | 189/18723 | 7.02e-09 | 1.02e-06 | 57 |
GO:00725214 | Colorectum | FAP | purine-containing compound metabolic process | 101/2622 | 416/18723 | 1.11e-08 | 1.33e-06 | 101 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0520820 | Cervix | CC | Chemical carcinogenesis - reactive oxygen species | 92/1267 | 223/8465 | 4.71e-22 | 5.09e-20 | 3.01e-20 | 92 |
hsa0516720 | Cervix | CC | Kaposi sarcoma-associated herpesvirus infection | 60/1267 | 194/8465 | 9.74e-09 | 1.58e-07 | 9.33e-08 | 60 |
hsa0520516 | Cervix | CC | Proteoglycans in cancer | 60/1267 | 205/8465 | 9.13e-08 | 1.18e-06 | 7.00e-07 | 60 |
hsa0491918 | Cervix | CC | Thyroid hormone signaling pathway | 33/1267 | 121/8465 | 3.11e-04 | 1.65e-03 | 9.78e-04 | 33 |
hsa0413718 | Cervix | CC | Mitophagy - animal | 22/1267 | 72/8465 | 5.77e-04 | 2.75e-03 | 1.63e-03 | 22 |
hsa046596 | Cervix | CC | Th17 cell differentiation | 28/1267 | 108/8465 | 1.99e-03 | 7.98e-03 | 4.72e-03 | 28 |
hsa052119 | Cervix | CC | Renal cell carcinoma | 20/1267 | 69/8465 | 2.07e-03 | 8.17e-03 | 4.83e-03 | 20 |
hsa0406618 | Cervix | CC | HIF-1 signaling pathway | 27/1267 | 109/8465 | 4.72e-03 | 1.64e-02 | 9.72e-03 | 27 |
hsa0523010 | Cervix | CC | Central carbon metabolism in cancer | 18/1267 | 70/8465 | 1.29e-02 | 3.87e-02 | 2.29e-02 | 18 |
hsa05208110 | Cervix | CC | Chemical carcinogenesis - reactive oxygen species | 92/1267 | 223/8465 | 4.71e-22 | 5.09e-20 | 3.01e-20 | 92 |
hsa05167110 | Cervix | CC | Kaposi sarcoma-associated herpesvirus infection | 60/1267 | 194/8465 | 9.74e-09 | 1.58e-07 | 9.33e-08 | 60 |
hsa0520517 | Cervix | CC | Proteoglycans in cancer | 60/1267 | 205/8465 | 9.13e-08 | 1.18e-06 | 7.00e-07 | 60 |
hsa0491919 | Cervix | CC | Thyroid hormone signaling pathway | 33/1267 | 121/8465 | 3.11e-04 | 1.65e-03 | 9.78e-04 | 33 |
hsa0413719 | Cervix | CC | Mitophagy - animal | 22/1267 | 72/8465 | 5.77e-04 | 2.75e-03 | 1.63e-03 | 22 |
hsa0465911 | Cervix | CC | Th17 cell differentiation | 28/1267 | 108/8465 | 1.99e-03 | 7.98e-03 | 4.72e-03 | 28 |
hsa0521114 | Cervix | CC | Renal cell carcinoma | 20/1267 | 69/8465 | 2.07e-03 | 8.17e-03 | 4.83e-03 | 20 |
hsa0406619 | Cervix | CC | HIF-1 signaling pathway | 27/1267 | 109/8465 | 4.72e-03 | 1.64e-02 | 9.72e-03 | 27 |
hsa0523013 | Cervix | CC | Central carbon metabolism in cancer | 18/1267 | 70/8465 | 1.29e-02 | 3.87e-02 | 2.29e-02 | 18 |
hsa05208 | Colorectum | AD | Chemical carcinogenesis - reactive oxygen species | 126/2092 | 223/8465 | 1.01e-24 | 1.68e-22 | 1.07e-22 | 126 |
hsa04066 | Colorectum | AD | HIF-1 signaling pathway | 48/2092 | 109/8465 | 7.25e-06 | 7.84e-05 | 5.00e-05 | 48 |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
HIF1A | MLUM | Breast | Healthy | TGM2,BZW1,NAMPT, etc. | 4.62e-01 | ![The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.](images/gene_regulatory/Breast/Str/TF_Healthy/regulons_activity_in_dotplot.png) |
HIF1A | MES | Cervix | CC | HIF1A-AS3,SNAPC1,KRT6C, etc. | 7.02e-01 | ![The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.](images/gene_regulatory/Cervix/Str/TF_CC/regulons_activity_in_dotplot.png) |
HIF1A | PERI | Colorectum | FAP | SSH1,NUAK1,RUNX1, etc. | 4.34e-02 | ![The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.](images/gene_regulatory/Colorectum/Str/TF_FAP/regulons_activity_in_dotplot.png) |
HIF1A | ICAF | Colorectum | SER | SSH1,NUAK1,RUNX1, etc. | 3.93e-01 | ![The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.](images/gene_regulatory/Colorectum/Str/TF_SER/regulons_activity_in_dotplot.png) |
HIF1A | PMC | Stomach | CAG with IM | PLPP3,SERPINA3,SOD2, etc. | 2.12e-01 | ![The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.](images/gene_regulatory/Stomach/Str/TF_CAG with IM/regulons_activity_in_dotplot.png) |
HIF1A | GMC | Stomach | CAG with IM | PLPP3,SERPINA3,SOD2, etc. | 1.31e-01 | ![The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.](images/gene_regulatory/Stomach/Str/TF_CAG with IM/regulons_activity_in_dotplot.png) |
HIF1A | PMC | Stomach | SIM | PLPP3,SERPINA3,SOD2, etc. | 4.96e-01 | ![The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.](images/gene_regulatory/Stomach/Str/TF_SIM/regulons_activity_in_dotplot.png) |
HIF1A | GMC | Stomach | WIM | PLPP3,SERPINA3,SOD2, etc. | 7.45e-02 | ![The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.](images/gene_regulatory/Stomach/Str/TF_WIM/regulons_activity_in_dotplot.png) |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
HIF1A | SNV | Missense_Mutation | novel | c.1022T>G | p.Val341Gly | p.V341G | Q16665 | protein_coding | deleterious(0) | probably_damaging(0.969) | TCGA-A8-A095-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
HIF1A | SNV | Missense_Mutation | rs540883086 | c.853N>A | p.Glu285Lys | p.E285K | Q16665 | protein_coding | deleterious(0) | possibly_damaging(0.473) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
HIF1A | SNV | Missense_Mutation | | c.1713N>T | p.Lys571Asn | p.K571N | Q16665 | protein_coding | tolerated(0.1) | probably_damaging(0.916) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
HIF1A | SNV | Missense_Mutation | novel | c.1752N>T | p.Glu584Asp | p.E584D | Q16665 | protein_coding | deleterious(0.01) | possibly_damaging(0.557) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
HIF1A | SNV | Missense_Mutation | rs746540920 | c.157N>T | p.Arg53Trp | p.R53W | Q16665 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
HIF1A | SNV | Missense_Mutation | | c.2485N>G | p.Pro829Ala | p.P829A | Q16665 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-BH-A0H5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | CR |
HIF1A | SNV | Missense_Mutation | | c.1996C>T | p.Pro666Ser | p.P666S | Q16665 | protein_coding | tolerated(0.1) | benign(0.01) | TCGA-BH-A18P-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
HIF1A | SNV | Missense_Mutation | rs776377120 | c.196C>T | p.His66Tyr | p.H66Y | Q16665 | protein_coding | deleterious(0.02) | benign(0.023) | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD |
HIF1A | SNV | Missense_Mutation | novel | c.2122C>G | p.His708Asp | p.H708D | Q16665 | protein_coding | tolerated(0.2) | benign(0.07) | TCGA-EA-A3HU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
HIF1A | SNV | Missense_Mutation | | c.412G>C | p.Asp138His | p.D138H | Q16665 | protein_coding | deleterious(0) | possibly_damaging(0.811) | TCGA-EK-A2PL-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
3091 | HIF1A | TRANSPORTER, TRANSCRIPTION FACTOR, ENZYME, DRUGGABLE GENOME, TRANSCRIPTION FACTOR COMPLEX, CLINICALLY ACTIONABLE | | SP-600125 | SP-600125 | |
3091 | HIF1A | TRANSPORTER, TRANSCRIPTION FACTOR, ENZYME, DRUGGABLE GENOME, TRANSCRIPTION FACTOR COMPLEX, CLINICALLY ACTIONABLE | | LEVONORDEFRIN | LEVONORDEFRIN | |
3091 | HIF1A | TRANSPORTER, TRANSCRIPTION FACTOR, ENZYME, DRUGGABLE GENOME, TRANSCRIPTION FACTOR COMPLEX, CLINICALLY ACTIONABLE | | DNDI1417388 | CHEMBL1528359 | |
3091 | HIF1A | TRANSPORTER, TRANSCRIPTION FACTOR, ENZYME, DRUGGABLE GENOME, TRANSCRIPTION FACTOR COMPLEX, CLINICALLY ACTIONABLE | | NOSCAPINE | NOSCAPINE | |
3091 | HIF1A | TRANSPORTER, TRANSCRIPTION FACTOR, ENZYME, DRUGGABLE GENOME, TRANSCRIPTION FACTOR COMPLEX, CLINICALLY ACTIONABLE | | NSC-117079 | CHEMBL471225 | |
3091 | HIF1A | TRANSPORTER, TRANSCRIPTION FACTOR, ENZYME, DRUGGABLE GENOME, TRANSCRIPTION FACTOR COMPLEX, CLINICALLY ACTIONABLE | | TYRPHOSTIN A9 | TYRPHOSTIN A9 | |
3091 | HIF1A | TRANSPORTER, TRANSCRIPTION FACTOR, ENZYME, DRUGGABLE GENOME, TRANSCRIPTION FACTOR COMPLEX, CLINICALLY ACTIONABLE | | PX-478 | PX-478 | |
3091 | HIF1A | TRANSPORTER, TRANSCRIPTION FACTOR, ENZYME, DRUGGABLE GENOME, TRANSCRIPTION FACTOR COMPLEX, CLINICALLY ACTIONABLE | | PIMOZIDE | PIMOZIDE | |
3091 | HIF1A | TRANSPORTER, TRANSCRIPTION FACTOR, ENZYME, DRUGGABLE GENOME, TRANSCRIPTION FACTOR COMPLEX, CLINICALLY ACTIONABLE | | BECLOMETHASONE | BECLOMETHASONE | |
3091 | HIF1A | TRANSPORTER, TRANSCRIPTION FACTOR, ENZYME, DRUGGABLE GENOME, TRANSCRIPTION FACTOR COMPLEX, CLINICALLY ACTIONABLE | | GELDANAMYCIN | GELDANAMYCIN | 12811834 |